Surgery for Stroke Prevention — Cost, Top Hospitals & Success Rates | MyMedicPlus

Stroke is the second leading cause of death worldwide and the leading cause of acquired long-term disability, affecting approximately 15 million people annually. Around 85% of strokes are ischaemic, and of these, roughly 20% are attributable to atherosclerotic disease of the extracranial carotid arteries. Surgical stroke prevention targets these correctable upstream causes — primarily carotid artery stenosis and patent foramen ovale (PFO) — in carefully selected patients before a stroke occurs or after a transient ischaemic attack (TIA) or minor stroke that signals a high-risk period.

The landmark NASCET (North American Symptomatic Carotid Endarterectomy Trial), published in the New England Journal of Medicine in 1991, established carotid endarterectomy (CEA) as the gold standard for symptomatic carotid stenosis. The trial demonstrated that CEA reduced the absolute risk of ipsilateral stroke at 5 years by 16 percentage points (from 26% to 9%) in patients with symptomatic stenosis of 70–99%, with a number needed to treat (NNT) of only 6 patients. For symptomatic stenosis of 50–69%, CEA still provided a 6.5% absolute risk reduction but required careful patient selection.

More recently, transcatheter patent foramen ovale (PFO) closure has been validated in three major randomised trials (CLOSE, RESPECT, REDUCE) as an effective strategy for secondary stroke prevention in patients under 60 with a cryptogenic stroke and a high-risk PFO, reducing the relative risk of recurrent stroke by 40–50% compared with antiplatelet therapy alone.

Choosing between CEA, carotid artery stenting (CAS), and optimal medical therapy (OMT) requires a multidisciplinary assessment incorporating imaging, stroke risk calculators, surgical risk stratification, and patient preference.

Surgical and catheter-based stroke prevention procedures are indicated for the following conditions:

• Symptomatic carotid artery stenosis (≥50%): Stenosis ipsilateral to a TIA, amaurosis fugax, or minor ischaemic stroke within the preceding 6 months; highest-risk period is within 2 weeks of the index event. NASCET criteria define severity by the distal normal internal carotid artery diameter.
• Asymptomatic carotid artery stenosis (≥60–70%): Detected incidentally on duplex ultrasound; annual stroke risk is lower (1–2% per year), so the benefit-to-risk ratio for surgery is narrower. Intervention is considered in patients with <3% perioperative risk, high-grade stenosis (≥80%), contralateral occlusion, or high-risk plaque features (echolucency, surface ulceration, intraplaque haemorrhage on MRI).
• Patent foramen ovale (PFO) with cryptogenic stroke: PFO is found in 50–60% of young patients with cryptogenic stroke, compared with 25% in the general population. High-risk PFO features warranting closure include large right-to-left shunt, atrial septal aneurysm, and a RoPE (Risk of Paradoxical Embolism) score ≥7.
• Carotid restenosis after prior CEA: Recurrent stenosis >80% may warrant CAS rather than repeat open surgery due to peri-neural scarring and higher cranial nerve injury risk.
• Radiation-induced carotid stenosis: Delayed arteritis and fibrosis from prior neck radiotherapy (e.g., for lymphoma, head and neck cancer) may cause severe stenosis; CAS is frequently preferred over CEA in this context due to the hostile surgical field.
• Vertebrobasilar atherosclerosis and intracranial disease: Selected patients with haemodynamic posterior circulation ischaemia unresponsive to OMT may be candidates for extracranial-intracranial bypass, though evidence is limited to specific phenotypes.

Patient selection for surgical stroke prevention requires a thorough vascular neurology and surgical evaluation. The following criteria guide decision-making:

Carotid Endarterectomy (CEA)

• Symptomatic stenosis 50–99% by NASCET criteria AND perioperative stroke/death risk <6% (verified by surgeon's audited outcomes); maximum benefit in stenosis 70–99%.
• Asymptomatic stenosis ≥60–70% AND perioperative risk <3%; the 2021 AHA/ASA guidelines note that contemporary OMT has narrowed the benefit of prophylactic surgery in asymptomatic patients, and shared decision-making is essential.
• Life expectancy >5 years — necessary to accrue long-term benefit over perioperative risk.
• No recent large disabling stroke (contraindication due to reperfusion haemorrhage risk within 4–6 weeks of major infarct).
• Adequate cardiac reserve — coronary artery disease must be optimised; myocardial infarction within 4–6 weeks is a relative contraindication.

Carotid Artery Stenting (CAS)

• High surgical risk patients (severe cardiac/pulmonary disease, age >80, hostile neck from prior surgery or radiation) where CEA carries increased perioperative risk.
• Contralateral internal carotid artery occlusion — bilateral surgery increases cranial nerve complication risk.
• CREST trial (2010) showed CAS is non-inferior to CEA at 4-year follow-up, but periprocedural stroke is higher with CAS in elderly patients (>70 years), while periprocedural MI risk is higher with CEA.

PFO Closure

• Age <60 years with confirmed cryptogenic ischaemic stroke (no other identified aetiology after full workup including Holter monitoring, echocardiography, hypercoagulability panel).
• High-risk PFO features: large shunt (>20 microbubbles on contrast TTE/TOE), associated atrial septal aneurysm (>10 mm excursion), or RoPE score ≥7.
• Neurological and cardiological clearance required; anticoagulation or antiplatelet therapy typically continued until device implantation.

Three primary interventional strategies exist for surgical stroke prevention, each with distinct mechanisms, procedural approaches, and evidence bases.

1. Carotid Endarterectomy (CEA)

CEA is performed under general or regional (cervical plexus block) anaesthesia. The common, internal, and external carotid arteries are exposed through a longitudinal neck incision, clamped, and the atheromatous plaque is surgically dissected and removed in continuity (endarterectomy). The arteriotomy is closed primarily or with a patch angioplasty (Dacron, PTFE, or autologous vein); patch closure reduces restenosis from 10% to 3–5% at 5 years and is now preferred at most centres.

Intraoperative cerebral monitoring (EEG, transcranial Doppler, stump pressure measurement, or near-infrared spectroscopy) identifies haemodynamic compromise during clamping and guides the decision to insert an intraluminal shunt. Operative time: 1.5–2.5 hours. The procedure should ideally be performed within 2 weeks of a symptomatic TIA or minor stroke to capture maximum benefit.

2. Carotid Artery Stenting (CAS)

CAS is a catheter-based endovascular procedure performed under local anaesthesia with conscious sedation. Access is obtained via the femoral artery (transfemoral) or increasingly via direct carotid or transradial access. An embolic protection device (EPD) — either a distal filter or proximal flow reversal balloon — is deployed before the stenosis is crossed with a guidewire and self-expanding nitinol stent. Post-dilation with a balloon catheter achieves optimal stent apposition. Dual antiplatelet therapy (aspirin + clopidogrel) is commenced at least 3–5 days before the procedure and continued for 30 days afterward.

3. Patent Foramen Ovale (PFO) Closure

Transcatheter PFO closure is performed under fluoroscopic and transesophageal or intracardiac echocardiographic guidance, usually under general anaesthesia or deep sedation. A catheter is advanced from the femoral vein through the PFO into the left atrium; a double-disc occluder device (Amplatzer PFO Occluder, Gore Cardioform) is deployed across the septum and positioned to straddle the foramen. Device endothelialisation occurs over 1–6 months. Three major randomised controlled trials (CLOSE, RESPECT extended follow-up, REDUCE) demonstrated a 40–50% relative risk reduction in recurrent stroke versus antiplatelet therapy alone, with an NNT of approximately 40 patients over 5 years.

Surgical stroke prevention procedures offer significant, evidence-based reductions in stroke risk in appropriately selected patients.

Carotid Endarterectomy

• Stroke risk reduction (symptomatic ≥70%): NASCET demonstrated a 65% relative risk reduction and 16% absolute risk reduction in ipsilateral stroke at 5 years; the benefit is greatest when surgery is performed within 2 weeks of the index event.
• Durable protection: CEA removes the entire atheromatous plaque; restenosis after patch closure occurs in only 3–5% at 5 years, providing long-lasting protection without long-term anticoagulation.
• Simultaneous diagnostic benefit: The excised plaque can be examined histologically for features such as intraplaque haemorrhage, thin fibrous cap, and lipid-rich necrotic core — confirming vulnerability and the appropriateness of intervention.
• Regional anaesthesia option: CEA under cervical plexus block allows neurological monitoring by keeping the patient awake, and is suitable for patients with high cardiac risk for whom general anaesthesia poses concern.

Carotid Artery Stenting

• Non-inferiority to CEA in 4-year composite outcomes (CREST trial), with significantly lower periprocedural MI risk (1.1% vs 2.3%).
• Less invasive: No neck incision; lower cranial nerve injury risk; performed under local anaesthesia; hospital stay of 1 day for most patients.
• Advantageous in hostile surgical fields: Preferred for radiation-induced stenosis, restenosis after prior CEA, and patients with previous radical neck dissection.

PFO Closure

• Relative risk reduction of 40–50% for recurrent cryptogenic stroke in patients aged <60 with high-risk PFO features, as demonstrated across three RCTs.
• Avoids long-term anticoagulation: After confirmed device closure at 12 months, anticoagulation can be discontinued, removing the bleeding risks and monitoring burden associated with warfarin or direct oral anticoagulants.
• Single intervention: One-time procedure with durable closure in >97% of patients.

All stroke prevention procedures carry procedural risks that must be weighed against the natural history stroke risk of untreated stenosis or PFO.

Carotid Endarterectomy (CEA)

• Perioperative stroke or TIA: 2–3% in experienced centres; primarily due to embolisation during carotid manipulation; the accepted threshold for symptomatic CEA is <6% combined stroke/death rate (AHA/ASA guidelines).
• Myocardial infarction: 1–2% perioperative MI due to haemodynamic stress; patients should have stable cardiac disease before surgery.
• Cranial nerve injury: The most common non-neurological complication; hypoglossal nerve (tongue deviation), marginal mandibular branch of the facial nerve (lower lip weakness), vagus nerve (hoarseness), and glossopharyngeal nerve may be affected transiently in 5–8% and permanently in <1%.
• Wound complications: Haematoma (3–5%), lymphocele, and wound infection (<1%). Neck haematoma is potentially life-threatening due to airway compression and requires emergency evacuation.
• Restenosis: 5–10% within 5 years, lower with patch angioplasty; restenosis may cause recurrent symptoms and require re-intervention.
• Hyperperfusion syndrome: Rare (<1%) but severe; restored blood flow to chronically hypoperfused brain causes oedema, severe headache, seizures, and intracerebral haemorrhage; risk is highest in patients with severe bilateral carotid disease.

Carotid Artery Stenting (CAS)

• Periprocedural stroke: 2–4% (higher than CEA in patients >70 years; CREST: 4.1% vs 2.3% in patients >70); embolic protection devices reduce but do not eliminate risk.
• In-stent restenosis: 3–6% at 5 years; managed with balloon dilation or stent-in-stent; generally lower than bare metal coronary stents due to lower-shear carotid flow.
• Access site complications: Femoral pseudoaneurysm, haematoma, arteriovenous fistula in 1–2%.
• Contrast nephropathy: Risk in patients with pre-existing renal impairment; iodinated contrast volume should be minimised and adequate hydration ensured.

PFO Closure

• New-onset atrial fibrillation: 3–6% in the 30–45 days after device implantation (CLOSE trial: 4.6%); usually self-limiting but requires anticoagulation and rhythm monitoring.
• Device embolisation: <1%; requires percutaneous or surgical retrieval.
• Residual shunt: 3–5% at 12 months; repeat closure or reassessment required for clinically significant residual shunt.
• Cardiac perforation / tamponade: Rare (<0.3%); requires emergency pericardiocentesis or surgery.

Structured post-procedural follow-up is essential for all surgical stroke prevention interventions to confirm technical success, monitor for complications, and optimise long-term secondary prevention.

After Carotid Endarterectomy

• Immediate post-op: Neurological assessment on waking from anaesthesia; blood pressure tightly controlled (target 120–150 mmHg systolic) to prevent hyperperfusion; carotid duplex ultrasound before discharge to confirm graft patency.
• Discharge: Typically 1–2 days post-operatively; aspirin 75–100 mg daily indefinitely; high-intensity statin therapy continued or initiated; wound check at 1–2 weeks.
• Duplex ultrasound surveillance: At 1 month, 6 months, 12 months, then annually; allows early detection of restenosis and contralateral disease progression.
• Risk factor control: LDL <1.8 mmol/L (<70 mg/dL) with statin; blood pressure target <130/80 mmHg; smoking cessation mandatory; HbA1c <7% in diabetics.

After Carotid Artery Stenting

• Dual antiplatelet therapy: Aspirin 75 mg + clopidogrel 75 mg daily for 30 days minimum post-CAS; then single antiplatelet (aspirin) indefinitely.
• Duplex surveillance: At 1 month, 6 months, and 12 months; in-stent restenosis identified and managed as above.
• Access site: Bed rest for 4–6 hours with femoral access; ambulation after haemostasis confirmed; access site inspected at 48 hours.

After PFO Closure

• Antiplatelet therapy: Aspirin 75–100 mg for 6 months post-implantation; dual antiplatelet in selected cases per centre protocol; anticoagulation discontinued after confirmed closure at 6–12 months.
• Echocardiography: Transthoracic echo with bubble study at 6 months and 12 months to confirm device position and closure; <5 microbubbles on Valsalva confirms complete closure.
• Cardiac rhythm monitoring: 30-day cardiac event monitor recommended at 3 months to screen for delayed atrial fibrillation.
• Neurology follow-up: At 3 and 12 months to confirm no recurrent neurological events; recurrent cryptogenic stroke warrants re-investigation for other aetiologies.

The cost of surgical stroke prevention varies significantly by procedure type, healthcare setting, and country.

Carotid Endarterectomy

• USA: $18,000–$35,000 (surgeon fee, anaesthesia, ICU/general ward stay, operative monitoring); higher in academic centres with intraoperative neurophysiology teams.
• India: $3,000–$6,000 at JCI-accredited hospitals including all perioperative care.
• UK (NHS): Covered at no cost to eligible patients with expedited pathway after TIA/minor stroke.
• Intraoperative neurophysiology monitoring: Adds $800–$1,500 per case in the USA but is standard of care at high-volume centres.

Carotid Artery Stenting

• Generally 15–30% more expensive than CEA due to device costs (stent, EPD: $3,000–$6,000 in device costs alone); total procedure cost $20,000–$45,000 in the USA.
• Shorter hospital stay (1 day vs 2–3 days) partially offsets procedural device costs.

PFO Closure

• Device cost alone: $3,500–$7,000 (Amplatzer PFO Occluder, Gore Cardioform); total procedural cost $25,000–$45,000 in the USA including catheterisation laboratory, sedation, and post-procedure monitoring.
• India, Thailand, and Eastern European centres offer PFO closure with equivalent device quality for $5,000–$10,000 total.

Ongoing Medical Costs

• Lifelong antiplatelet therapy (aspirin: minimal cost); statin therapy; blood pressure medications; 5-year duplex surveillance programme.
• Secondary prevention programme costs should be factored into the total cost of stroke prevention management.

Not all patients with carotid stenosis or PFO require surgical intervention. Optimal medical therapy (OMT) is the appropriate primary strategy for many patients and a mandatory adjunct for all who undergo surgery.

Optimal Medical Therapy (OMT)

• Antiplatelet therapy: Aspirin 75–100 mg daily, or clopidogrel 75 mg daily as an alternative; for the first 21 days after a TIA or minor stroke, POINT and CHANCE trials support dual antiplatelet therapy (aspirin + clopidogrel) for high-risk non-cardioembolic events, reducing 90-day stroke risk by ~25%.
• High-intensity statin therapy: Atorvastatin 40–80 mg or rosuvastatin 20–40 mg daily; target LDL <1.8 mmol/L; statins reduce carotid plaque inflammation and stabilise vulnerable plaque, reducing embolic risk independent of plaque stenosis severity.
• Antihypertensive therapy: ACE inhibitor or ARB plus calcium channel blocker; target <130/80 mmHg; every 10 mmHg systolic reduction reduces stroke risk by 22% (PROGRESS trial).
• Lifestyle modification: Smoking cessation (halves stroke risk within 5 years); Mediterranean diet (PREDIMED trial: 30% stroke risk reduction); physical activity 150 minutes/week moderate intensity; weight reduction.

Anticoagulation

• Indicated for cardioembolic stroke aetiology (atrial fibrillation, mechanical heart valves, intracardiac thrombus); warfarin or DOACs (apixaban, rivaroxaban) reduce cardioembolic stroke by 60–70% compared with no treatment. Not superior to antiplatelet therapy for large artery atherosclerosis.

Endovascular Alternatives for Intracranial Disease

• Intracranial angioplasty and stenting: For symptomatic intracranial atherosclerotic stenosis ≥70% unresponsive to OMT; SAMMPRIS trial showed best medical therapy is superior to Wingspan stenting for most patients due to high perioperative risk; reserved for very selected cases.